Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of SYS6045 in HER2-positive, HER2-expressing, or HER2-mutant advanced solid tumors
CTR20252942Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6045 in Nonhematologic neoplasms, breast cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
SYS6045
03
Conditions
Nonhematologic neoplasmsbreast cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252942.